Combination medicines: is there a place for such products?'
The Medico-Pharmaceutical Forum held a discussion on combination medicines at the Royal Society of Medicine on 3 June 1981, chaired by Professor W Linford Rees.
Dr G R Tudhope from the Department of Pharmacology & Therapeutics at the University of Dundee opened by defining the products more precisely as 'fixed-ratio drug combinations'. He recognized the benefit of convenience claimed for such products but felt that many older ones failed to satisfy any criteria of rational therapeutics and noted that an expert panel in the USA in the mid-1960s had found only 45 out of 1200 to be effective. However, that was many years ago and many current combinations playa valuable role in modern therapeutics. He went on to give examples and to balance the points for and against fixeddose combinations. The most important point in favour was better compliance and convenience for essential multiple therapy, and against was the ignorant use of one of the ingredients. Dr Tudhope concluded that combinations were a heterogeneous group which could not be considered together, and the answer to the question posed by the title must be yes for some and no for others.
Dr D Wheatley of the General Practitioner Research Group then spoke of the pattern of prescribing in earlier years when virtually all prescriptions were combinations. He drew attention to the continued availability of very many combinations today, as shown by an analysis from M1MS. In going over the various categories of combination products, he emphasized the importance of achieving compliance in an elderly population where unsupervised, multiple drug therapy was often the rule. In particular, he made the point that most general practitioners would prefer their elderly hypertensive patients to have a combined product that was easy to take, even if it did not achieve perfect control of blood pressure, rather than a more complicated regimen that had little chance of being followed accurately. Nevertheless, he found it difficult to justify some combinations such as analgesics and antibiotics. His conclusion, was that while some combination products seem illogical, many provide excellent clinical advantages to the general practitioner.
The final speaker was Dr E S Snell of the Association of the British Pharmaceutical Industry, who felt that combinations must justify themselves as must any other medicine. However, 1 Report of meeting of the Medico-Pharmaceutical Forum, 3 June 1981. Accepted 13 July 1981 0141-0768/81/100775-01/$01.00/0 the recent British National Formulary commented, in one section, that it could not recommend combinations of agents with similar actions and, in another section, agents. with different actions, thus virtually excluding all such products. Dr Snell outlined the complicated response to a single agent, which often resulted in multiple chemical agents as well as many pharmacological actions both in fixed ratios. The specifically designed and comprehensively tested multiple actions of a combination compared favourably with the effects of many single entities or the untested chance effectsof much multiple prescribing. An analysis of the top 100products prescribed in general practice and at the Aberdeen Royal Infirmary showed that 33% and 20% respectively of prescriptions were combinations. It was more important to discuss combinations that were widely used than those which were just available. Despite the reassuring evidence of clinical practice, the apparent doctrinal antagonism to fixed-dose combinations in the UK was having a major effect in inhibiting pharmaceutical research, where scientists and doctors were unwilling to devote their efforts to useful products of this kind which they felt would never get a licence.
In the very lively discussion which followed, all agreed that combination products should have the same evidence of safety and efficacyas any singleentity medicine. Past and present members of UK regulatory committees and the BNF denied any doctrinal discrimination against fixed-dosage combinations, but doctors from the phannaceutical industry pointed out that different standards of proof seemed to be required and that combinations had to show superior efficacy, rather than just efficacy,as compared with singleentity medicines. However, the Chairman stated that neither the Committee on Safety of Medicines nor the Committee on the Review of Medicines looked at comparative efficacy and that equal standards should apply to all medicinal products, whether they were combinations or single-dose entities.
A number of contributors welcomed this statement and hoped that it would help to overcome the prejudice that had been expressed by speakers both from the pharmaceutical industry and from medical practice.
In winding up the discussion, Professor Linford Rees recognized that the subject affected all prescribing doctors, and the Forum had been right to arrange a discussion which had covered aspects of it that many people may not previously have appreciated.
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